Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Tiziana Life Sciences given green light to expand clinical trial

The company delivered an encouraging update on its progress with its treatment for liver cancer
liver in x-ray
Those currently receiving the new treatment have a very hard to treat form hepatocellular carcinoma

Tiziana Life Sciences PLC (LON:TILS) has been allowed to expand the clinical trial of its cancer drug milciclib.

The green light follows a second interim review by the independent data monitor committee monitoring the phase IIa study.

It found the drug to be reasonably well tolerated by the 11 people taking the new medication with an "acceptable incidence of serious adverse events" reported.

Those currently receiving the new treatment have a very hard to treat form hepatocellular carcinoma (HCC), the most common type of liver cancer.

Seriously ill patients opt to continue with drug

Four patients so far have completed the full treatment cycle with two opting to continue taking the drug under a protocol for compassionate use. 

third is awaiting ethical committee approval to do the same thing.

Tiziana will now enrol an additional 20 liver cancer sufferers to the trial. 

The drug developer said the latest update represented an "important milestone", allowing the company to kick-off a phase IIb assessment of milciclib in harness with sorafenib, the current front-line treatment.

Chief executive Kunwar Shailubhai added: "Results from these clinical studies strongly warrant further clinical development of milciclib for treatments of HCC and other cancers."


View full TILS profile View Profile

Tiziana Life Sciences Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use